Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna and Merck have announced that their personalized mRNA cancer vaccine, Intismeran, successfully reduced the risk of melanoma recurrence and spread in late-stage trials. The results represent a significant milestone in mRNA technology, potentially offering a new treatment pathway for high-risk patients.
Why it matters
This breakthrough validates the application of mRNA technology beyond infectious diseases, signaling a major shift in oncology treatment options.
Moderna’s mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
x whatsapp-stroke copylink google Add Al Jazeera on Google info Moderna and Merck said the treatment met key trial goals and could offer a new option for patients with high-risk melanoma [File: AFP] By Al Jazeera Staff and Reuters Published On 19 Aug 2026 19 Aug 2026 Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much as 160 percent.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in